Pharmacotherapy in alcohol problems

Current Opinion in Psychiatry

Volumn 11, Issue 3, 1998, Pages 285-288

  Ritson, Bruce ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; DISULFIRAM; DOPAMINE; GLUTAMIC ACID; NALTREXONE; OPIATE ANTAGONIST; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL WITHDRAWAL; ALCOHOLISM; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; PATIENT COMPLIANCE; PRACTICE GUIDELINE; SHORT SURVEY;

EID: 0031894121     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199805000-00008     Document Type: Short Survey

References (20)

1. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997; 278:144-151. An authoritative review is presented that is based on extensive meta-analysis.
2. Hughes HC, Cook CCH. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92:381-395. This is an excellent review of the current place of disulfiram in therapy and consideration of future research questions.
3. Pettinati HM. Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 1996; 20:23-29.
4. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioural therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20:1534-1541.
5. Lesch OM, Waller H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 1996; 31 (suppl 1):63-67.
6. O'Malley SS, Carroll KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res 1996; 20 (suppl):17-22.
7. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996; 20:1412-1417. This is an interesting consideration of the evidence that previous studies may not have used sufficient riboflavin tracer to monitor compliance.
8. Anton RF. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res 1996; 20 (suppl):3-9.
9. Volpicelli JR, Allemeir AI, Hayashido M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Acute Gen Psychiatry 1992; 49:876-880.
10. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE. Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence - a controlled study. Arch Gen Psychiatry 1992; 49:881-887.
11. King AC, Volpicelli JR, Frazer A, O'Brien CP. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 1997; 129:15-22.
12. Mason BJ. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res 1996; 20 (suppl):10-16.
13. Jaffe AJ, Rounsaville B, Chang G, Shottenfeld RS, Meyer RF, O'Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64:1044-1053. Ninety-seven alcohol-dependent patients in this random control study were given naltrexone or placebo with supportive or relapse prevention therapy: analyses of interaction between drug and psychological therapy are provided.
14. Lejoyeux M, Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol 1996; 31 (suppl 1): 69-75.
15. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, et al. Ritanserin in the treatment of alcohol dependence - A multi-center clinical trial. Psychopharmacology (Berl) 1996; 128:206-215.
16. Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21:86-92.
17. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T. et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 34:1438-1442. This double blind, placebo-controlled study of 455 patients with alcohol dependence treated for 1 year with acamprosate showed significant benefits in a number of measures, including time to first drink.
18. Sass H. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53:673-680. This randomized, double blind, placebo-controlled study of 272 patients with alcohol dependence treated for 48 weeks and followed up for a further 48 weeks showed significantly greater abstinence over 2 years.
19. Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R. A double blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology (Berl) 1997; 131:123-129.
20. Litten RZ, Fertig J. International update: new findings on promising medications. Alcohol Clin Exp Res 1996; 20 (suppl):216-218.